BFC Planning’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.1K Sell
2,697
-5,702
-68% -$19.3K ﹤0.01% 2324
2026
Q2
$30.8K Buy
8,399
+2,045
+32% +$6.81K ﹤0.01% 1786
2026
Q1
$19.5K Sell
6,354
-10
-0.2% -$39 ﹤0.01% 1723
2025
Q4
$26K Sell
6,364
-2,320
-27% -$11.5K ﹤0.01% 1628
2025
Q3
$42.4K Buy
8,684
+2,000
+30% +$10.5K ﹤0.01% 1257
2025
Q2
$33.8K Buy
6,684
+5,000
+297% +$24.6K ﹤0.01% 1277
2025
Q1
$8.91K Buy
1,684
+182
+12% +$1.33K ﹤0.01% 1820
2024
Q4
$10.2K Buy
1,502
+1,172
+355% +$7.88K ﹤0.01% 1757
2024
Q3
$2.18K Buy
+330
New +$2.37K ﹤0.01% 2262

Other funds holding RXRX

BFC Planning's RXRX Position: Q3 2026 in Review

BFC Planning reduced its Recursion Pharmaceuticals (RXRX) stake by 68% in Q3 2026, selling an estimated $19.3K and leaving 2,697 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2324.

BFC Planning first reported a position in RXRX in Q3 2024 and has held it in 9 quarters since. The position peaked at $42.4K in Q3 2025. 272 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • BFC Planning held 2,697 shares of Recursion Pharmaceuticals worth $11.1K as of Q3 2026.
  • BFC Planning sold 5,702 Recursion Pharmaceuticals shares in Q3 2026, an estimated $19.3K.
  • Recursion Pharmaceuticals made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2324 holding.
  • BFC Planning first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Recursion Pharmaceuticals position peaked at $42.4K in Q3 2025.
  • 272 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.